Braun Stacey Associates Inc. Grows Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Braun Stacey Associates Inc. lifted its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 4.9% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 103,012 shares of the biotechnology company's stock after buying an additional 4,827 shares during the quarter. Braun Stacey Associates Inc. owned approximately 0.11% of Sarepta Therapeutics worth $12,865,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of SRPT. Farallon Capital Management LLC lifted its position in shares of Sarepta Therapeutics by 102.8% in the first quarter. Farallon Capital Management LLC now owns 2,453,500 shares of the biotechnology company's stock valued at $317,630,000 after acquiring an additional 1,243,427 shares in the last quarter. Principal Financial Group Inc. boosted its stake in Sarepta Therapeutics by 693.7% in the 2nd quarter. Principal Financial Group Inc. now owns 363,011 shares of the biotechnology company's stock worth $57,356,000 after purchasing an additional 317,277 shares during the period. Canada Pension Plan Investment Board boosted its stake in Sarepta Therapeutics by 2,257.8% in the 1st quarter. Canada Pension Plan Investment Board now owns 240,500 shares of the biotechnology company's stock worth $31,135,000 after purchasing an additional 230,300 shares during the period. Rhumbline Advisers grew its holdings in Sarepta Therapeutics by 146.3% during the 2nd quarter. Rhumbline Advisers now owns 270,941 shares of the biotechnology company's stock valued at $42,809,000 after buying an additional 160,942 shares in the last quarter. Finally, Blair William & Co. IL raised its position in shares of Sarepta Therapeutics by 303.7% during the second quarter. Blair William & Co. IL now owns 174,282 shares of the biotechnology company's stock valued at $27,537,000 after buying an additional 131,112 shares during the last quarter. Institutional investors own 86.68% of the company's stock.

Sarepta Therapeutics Trading Down 0.2 %

Shares of NASDAQ:SRPT traded down $0.22 on Monday, hitting $104.32. 697,087 shares of the company's stock were exchanged, compared to its average volume of 1,232,424. The stock has a market capitalization of $9.96 billion, a price-to-earnings ratio of 83.63 and a beta of 0.81. Sarepta Therapeutics, Inc. has a 12 month low of $78.67 and a 12 month high of $173.25. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. The business's 50 day simple moving average is $123.72 and its two-hundred day simple moving average is $132.38.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on SRPT shares. Royal Bank of Canada restated an "outperform" rating and set a $182.00 target price on shares of Sarepta Therapeutics in a research report on Monday, October 21st. UBS Group raised their price objective on Sarepta Therapeutics from $173.00 to $188.00 and gave the company a "buy" rating in a research report on Tuesday, September 17th. William Blair raised Sarepta Therapeutics to a "strong-buy" rating in a report on Friday, August 30th. Cantor Fitzgerald raised Sarepta Therapeutics from a "neutral" rating to an "overweight" rating and increased their price target for the company from $152.00 to $167.00 in a research note on Thursday, November 7th. Finally, Guggenheim lifted their price objective on Sarepta Therapeutics from $148.00 to $150.00 and gave the stock a "buy" rating in a research note on Thursday, November 7th. One analyst has rated the stock with a hold rating, twenty-one have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $181.33.

Insiders Place Their Bets

In other Sarepta Therapeutics news, CFO Ian Michael Estepan sold 5,985 shares of the company's stock in a transaction on Friday, August 30th. The stock was sold at an average price of $137.36, for a total transaction of $822,099.60. Following the completion of the sale, the chief financial officer now owns 33,946 shares in the company, valued at $4,662,822.56. This represents a 14.99 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 7.70% of the company's stock.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.